Case Report: Dual Inhibition of HDAC and BTK for Diffuse Large B-Cell Lymphoma After Failure to CD19-Targeted CAR-T Therapy
BackgroundFailure to CD19-targeted chimeric antigen receptor T-cell (CAR-T) therapy for patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), is an emerging clinical problem. There is no consensus on the treatment for these patients and treatment remains empirical.Case Repor...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-06-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.894787/full |
| _version_ | 1818536179157434368 |
|---|---|
| author | Weiguo Zhu Shi Tao Wenchun Miao Hui Liu Xianggui Yuan |
| author_facet | Weiguo Zhu Shi Tao Wenchun Miao Hui Liu Xianggui Yuan |
| author_sort | Weiguo Zhu |
| collection | DOAJ |
| description | BackgroundFailure to CD19-targeted chimeric antigen receptor T-cell (CAR-T) therapy for patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), is an emerging clinical problem. There is no consensus on the treatment for these patients and treatment remains empirical.Case ReportWe reported a case of an elderly R/R DLBCL patient who had TP53 mutation and relapsed 12 months after initial response to CAR T-cell therapy. The patient did not respond to salvage chemotherapy with the GDP regimen and could not tolerate any aggressive chemotherapy. Thereafter, the patient was given chidamide and zanubrutinib. After two months of treatment, the patient achieved sustained complete remission. At the last follow-up, the patient remains in radiographic CR 22 months after CAR-T infusion and 10 months after the initiation of the combination treatment.ConclusionWe report the first successful case of dual inhibition of HDAC and BTK for the treatment of R/R DLBCL after failure to CAR-T cell therapy, which opens a new therapeutic possibility for the future. |
| first_indexed | 2024-12-11T18:34:36Z |
| format | Article |
| id | doaj.art-7c25369d65cf4fb39ce283af866af50a |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-12-11T18:34:36Z |
| publishDate | 2022-06-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-7c25369d65cf4fb39ce283af866af50a2022-12-22T00:54:49ZengFrontiers Media S.A.Frontiers in Immunology1664-32242022-06-011310.3389/fimmu.2022.894787894787Case Report: Dual Inhibition of HDAC and BTK for Diffuse Large B-Cell Lymphoma After Failure to CD19-Targeted CAR-T TherapyWeiguo Zhu0Shi Tao1Wenchun Miao2Hui Liu3Xianggui Yuan4Department of Hematology, Shaoxing Second Hospital, Shaoxing, ChinaDepartment of Hematology, Shaoxing Second Hospital, Shaoxing, ChinaDepartment of Hematology, Shaoxing Second Hospital, Shaoxing, ChinaDepartment of Hematology, The Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, ChinaDepartment of Hematology, The Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, ChinaBackgroundFailure to CD19-targeted chimeric antigen receptor T-cell (CAR-T) therapy for patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), is an emerging clinical problem. There is no consensus on the treatment for these patients and treatment remains empirical.Case ReportWe reported a case of an elderly R/R DLBCL patient who had TP53 mutation and relapsed 12 months after initial response to CAR T-cell therapy. The patient did not respond to salvage chemotherapy with the GDP regimen and could not tolerate any aggressive chemotherapy. Thereafter, the patient was given chidamide and zanubrutinib. After two months of treatment, the patient achieved sustained complete remission. At the last follow-up, the patient remains in radiographic CR 22 months after CAR-T infusion and 10 months after the initiation of the combination treatment.ConclusionWe report the first successful case of dual inhibition of HDAC and BTK for the treatment of R/R DLBCL after failure to CAR-T cell therapy, which opens a new therapeutic possibility for the future.https://www.frontiersin.org/articles/10.3389/fimmu.2022.894787/fulldiffuse large B-cell lymphomachimeric antigen receptor T cellchidamidezanubrutinibhistone deacetylase inhibitorBruton’s tyrosine kinase inhibitor |
| spellingShingle | Weiguo Zhu Shi Tao Wenchun Miao Hui Liu Xianggui Yuan Case Report: Dual Inhibition of HDAC and BTK for Diffuse Large B-Cell Lymphoma After Failure to CD19-Targeted CAR-T Therapy Frontiers in Immunology diffuse large B-cell lymphoma chimeric antigen receptor T cell chidamide zanubrutinib histone deacetylase inhibitor Bruton’s tyrosine kinase inhibitor |
| title | Case Report: Dual Inhibition of HDAC and BTK for Diffuse Large B-Cell Lymphoma After Failure to CD19-Targeted CAR-T Therapy |
| title_full | Case Report: Dual Inhibition of HDAC and BTK for Diffuse Large B-Cell Lymphoma After Failure to CD19-Targeted CAR-T Therapy |
| title_fullStr | Case Report: Dual Inhibition of HDAC and BTK for Diffuse Large B-Cell Lymphoma After Failure to CD19-Targeted CAR-T Therapy |
| title_full_unstemmed | Case Report: Dual Inhibition of HDAC and BTK for Diffuse Large B-Cell Lymphoma After Failure to CD19-Targeted CAR-T Therapy |
| title_short | Case Report: Dual Inhibition of HDAC and BTK for Diffuse Large B-Cell Lymphoma After Failure to CD19-Targeted CAR-T Therapy |
| title_sort | case report dual inhibition of hdac and btk for diffuse large b cell lymphoma after failure to cd19 targeted car t therapy |
| topic | diffuse large B-cell lymphoma chimeric antigen receptor T cell chidamide zanubrutinib histone deacetylase inhibitor Bruton’s tyrosine kinase inhibitor |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2022.894787/full |
| work_keys_str_mv | AT weiguozhu casereportdualinhibitionofhdacandbtkfordiffuselargebcelllymphomaafterfailuretocd19targetedcarttherapy AT shitao casereportdualinhibitionofhdacandbtkfordiffuselargebcelllymphomaafterfailuretocd19targetedcarttherapy AT wenchunmiao casereportdualinhibitionofhdacandbtkfordiffuselargebcelllymphomaafterfailuretocd19targetedcarttherapy AT huiliu casereportdualinhibitionofhdacandbtkfordiffuselargebcelllymphomaafterfailuretocd19targetedcarttherapy AT xiangguiyuan casereportdualinhibitionofhdacandbtkfordiffuselargebcelllymphomaafterfailuretocd19targetedcarttherapy |